Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Pyrotinib/Capecitabine Effective for HER2-Positive Metastatic Breast Cancer

Pyrotinib, an irreversible pan-ErbB inhibitor, provides an effective treatment option in combination with capecitabine for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, according to results of a phase 3 trial to be presented later this month in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The open-label, multicenter PHOEBE trial enrolled patients with HER2-positive metastatic breast cancer following treatment ...
Continue reading

Tucatinib Approved: Metastatic HER2-Positive Breast Cancer

The FDA has now approved tucatinib (TukysaTM, Seattle Genetics) in combination with trastuzumab and capecitabine for adults with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously treated with at least one anti-HER2-based regimen in the metastatic setting. The tucatinib indication includes patients with brain metastases.The approval for tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, is based on data from HER2CLIMB (...
Continue reading

Neratinib: Progress for HER2-Positive Metastatic Breast Cancer With Adam Brufsky, MD, PhD, FACP

Last week, the FDA added a second approval for neratinib (Nerlynx​®​, Puma Biotechnology, Inc.) in combination with capecitabine for adults with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer previously treated with at least two anti-HER2–based regimens in the metastatic setting. This adds to the previous approval of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, for the extended adjuvant treatment of early-stage HER2-positive breast cancer followi...
Continue reading

Neratinib Approved: HER2-Positive Metastatic Breast Cancer

The FDA has approved a supplemental New Drug Application (sNDA) for neratinib (Nerlynx®, Puma Biotechnology, Inc.) in combination with capecitabine for adults with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer previously treated with at least two anti-HER2–based regimens in the metastatic setting. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), has previously been approved for the extended adjuvant treatment of adults with early...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.